|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/10/13 Opko Health, Inc. 10-Q 3/31/13 76:9.1M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 632K
2: EX-2.10 Plan of Acquisition, Reorganization, Arrangement, HTML 369K
Liquidation or Succession
3: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 28K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 21K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 21K
52: R1 Document and Entity Information HTML 41K
40: R2 Condensed Consolidated Balance Sheets (Unaudited) HTML 147K
50: R3 Condensed Consolidated Balance Sheets (Unaudited) HTML 73K
(Parenthetical)
54: R4 Condensed Consolidated Statements of Operations HTML 116K
(Unaudited)
70: R5 Condensed Consolidated Statements of Comprehensive HTML 42K
Loss (Unaudited)
42: R6 Condensed Consolidated Statement of Shareholders' HTML 95K
Equity (Unaudited)
49: R7 Condensed Consolidated Statement of Shareholders' HTML 25K
Equity (Unaudited) (Parenthetical)
36: R8 Condensed Consolidated Statements of Cash Flows HTML 185K
(Unaudited)
27: R9 Business and Organization HTML 34K
71: R10 Summary of Significant Accounting Policies HTML 48K
56: R11 Loss Per Share HTML 28K
55: R12 Composition of Certain Financial Statement HTML 60K
Captions
61: R13 Acquisitions, Investments, and Licenses HTML 107K
62: R14 Debt HTML 87K
59: R15 Accumulated Other Comprehensive Income HTML 37K
63: R16 Fair Value Measurements HTML 158K
51: R17 Derivative Contracts HTML 71K
53: R18 Related Party Transactions HTML 40K
58: R19 Commitments and Contingencies HTML 33K
76: R20 Segments HTML 68K
66: R21 Series D Preferred Stock Redemption HTML 35K
45: R22 Subsequent Events HTML 25K
57: R23 Summary of Significant Accounting Policies HTML 119K
(Policies)
47: R24 Composition of Certain Financial Statement HTML 59K
Captions (Tables)
20: R25 Acquisitions, Investments, and Licenses (Tables) HTML 95K
67: R26 Debt (Tables) HTML 86K
73: R27 Accumulated Other Comprehensive Income (Tables) HTML 32K
31: R28 Fair Value Measurements (Tables) HTML 158K
30: R29 Derivative Contracts (Tables) HTML 65K
34: R30 Segments (Tables) HTML 59K
35: R31 Summary of Significant Accounting Policies HTML 60K
(Details)
37: R32 Loss Per Share (Details) HTML 33K
18: R33 Composition of Certain Financial Statement HTML 124K
Captions (Details)
64: R34 Acquisitions, Investments, and Licenses (Details) HTML 43K
44: R35 Acquisitions, Investments, and Licenses (Details HTML 31K
1)
46: R36 Acquisitions, Investments, and Licenses (Details HTML 67K
2)
23: R37 Acquisitions, Investments, and Licenses (Details HTML 90K
3)
75: R38 Acquisitions, Investments, and Licenses (Details HTML 193K
Textual)
13: R39 Debt (Details) HTML 38K
38: R40 Debt (Details 1) HTML 27K
69: R41 Debt (Details 2) HTML 33K
22: R42 Debt (Details 3) HTML 53K
29: R43 Debt (Details 4) HTML 33K
33: R44 Debt (Details Textual) HTML 86K
41: R45 Accumulated Other Comprehensive Income (Details) HTML 49K
17: R46 Accumulated Other Comprehensive Income (Details HTML 34K
Textual)
26: R47 Fair Value Measurements (Details) HTML 47K
15: R48 Fair Value Measurements (Details 1) HTML 57K
68: R49 Fair Value Measurements (Details 2) HTML 31K
21: R50 Fair Value Measurements (Details 3) HTML 45K
65: R51 Fair Value Measurements (Details Textual) HTML 51K
24: R52 Derivative Contracts (Details) HTML 30K
39: R53 Derivative Contracts (Details 1) HTML 27K
14: R54 Derivative Contracts (Details 2) HTML 38K
16: R55 Derivative Contracts (Details Textual) HTML 27K
32: R56 Related Party Transactions (Details) HTML 172K
19: R57 Commitments and Contingencies (Details) HTML 41K
72: R58 Segments (Details) HTML 67K
43: R59 Segments (Details Textual) HTML 45K
60: R60 Series D Preferred Stock Redemption (Details) HTML 36K
25: R61 Subsequent Events (Details) HTML 33K
74: XML IDEA XML File -- Filing Summary XML 113K
28: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 1.36M
7: EX-101.INS XBRL Instance -- opk-20130331 XML 1.97M
9: EX-101.CAL XBRL Calculations -- opk-20130331_cal XML 231K
10: EX-101.DEF XBRL Definitions -- opk-20130331_def XML 978K
11: EX-101.LAB XBRL Labels -- opk-20130331_lab XML 1.51M
12: EX-101.PRE XBRL Presentations -- opk-20130331_pre XML 1.14M
8: EX-101.SCH XBRL Schema -- opk-20130331 XSD 232K
48: ZIP XBRL Zipped Folder -- 0001193125-13-212997-xbrl Zip 193K
| EX-31.1 |
Exhibit 31.1
CERTIFICATIONS
I, Phillip Frost, certify that:
| (1) | I have reviewed this Quarterly Report on Form 10-Q of OPKO Health, Inc.; |
| (2) | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| (3) | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| (4) | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| (c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| (d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| (5) | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Date: May 10, 2013 | ||||||
| Dr. Phillip Frost, M.D. | ||||||
| Chief Executive Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/10/13 | 4, 8-K | ||
| For Period end: | 3/31/13 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/18/21 Opko Health, Inc. 10-K 12/31/20 111:16M |